Originally Posted by
catherine
I have done a couple of market research projects for pharmaceutical companies engaged in clinical trials. Basically, clinical trial participants are heavily skewed towards white males. So that means the clinical trial results may not be truly reflective of the general population because they can differ for people with various genetic profiles, so it is an issue of interest and concern. In particular, Black, Asian, and Latino/Hispanic communities aren't being recruited because it's faster to recruit white people, and also, there is a high degree of fear on the part of Black people due to historical abuses in clinical trials, and the Latino/Hispanic population is concerned about their data security.
I truly hope that this administration doesn't target DEI efforts in clinical trials.